The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InReflecting a period of divergent performance across healthcare tech and industrial sectors, three major US corporations released their Q2 2026 financial results. Thermo Fisher Scientific delivered a decisive 'double beat' against analyst consensus, reporting adjusted EPS of $6.03 against the $5.72 expected, and revenues of $11.99 billion which surpassed the $11.71 billion forecast. Meanwhile, Honeywell announced sales of $9.7 billion, while Cleveland-Cliffs faced a GAAP net loss of $134 million despite revenues increasing to $5.2 billion.
Per market data, these results highlight varying operational strengths relative to FactSet analyst estimates. Thermo Fisher (TMO) closed at $526.46 (as of July 22, 2026) following its earnings beat, while Honeywell (HON) stood at $229.86 (as of July 21, 2026). Cleveland-Cliffs (CLF) closed at $9.45 (as of July 22, 2026), with its stock price reflecting the impact of the reported net loss despite the topline revenue growth.
Traders should watch for support levels in CLF following its recent move, as it hit a day low of $9.25 on July 22, 2026. Broader industrial sentiment may also be influenced by recent macro data, such as the Philadelphia Fed Manufacturing Index which came in at 41.4, significantly beating forecasts and potentially signaling future demand shifts for industrial and materials firms.